Oncolytic measles vaccines encoding PD-1 and PD-L1 checkpoint blocking antibodies to increase tumor-specific T cell memory

Rūta Veinalde,1,8 Gemma Pidelaserra-Martí,1,2,3 Coline Moulin,2,4 Lara M. Jeworowski,1,9 Linda Küther,2 Christian J. Buchholz,5 Dirk Jäger,6,7 Guy Ungerechts,1,6 and Christine E. Engeland1,2,6

1Clinical Cooperation Unit Virotherapy, German Cancer Research Center, Im Neuenheimer Feld 242, 69120 Heidelberg, Germany; 2Faculty of Health, School of Medicine, Center for Biomedical Research and Education, Institute of Virology and Microbiology, Witten/Herdecke University, Stockumer Str. 10, 58453 Witten, Germany; 3Faculty of Biosciences, Heidelberg University, 69120 Heidelberg, Germany; 4Ecole Normale Supérieure de Lyon, 15 parvis René Descartes, 69342 Lyon, France; 5Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225 Langen, Germany; 6Department of Medical Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany; 7Clinical Cooperation Unit Applied Tumor Immunity, German Cancer Research Center, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany

---

INTRODUCTION

The discovery of molecules that inhibit immune cell activation and the development of the immune checkpoint concept provided a basis for successful cancer immunotherapy strategies.1,2 Programmed cell death protein 1 (PD-1 or CD279) is an immune checkpoint molecule that is upregulated on T cells upon T cell receptor (TCR) engagement and mediates peripheral immune tolerance. Besides activated T cells, PD-1 can be expressed on other types of immune cells, including natural killer (NK) cells, NKT cells, B cells and some populations of antigen-presenting cells (APCs), and even cancer cells. In many types of cancer, expression of PD-1 or its ligands programmed cell death ligand 1 (PD-L1 or CD274) and PD-L2 (CD273) is sustained at high levels.3 PD-1/PD-L1 blockade with monoclonal antibodies has proved to be a successful therapeutic strategy to reinvigorate anti-tumor immunity.4 Six different monoclonal antibodies for PD-1/PD-L1 blockade have been approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for treatment of a range of different cancer types.5 Although PD-1/PD-L1 blocking antibodies can achieve impressive therapeutic effects in some individuals, at least half of treated patients do not respond to therapy.2 A major factor for resistance to PD-1/PD-L1 blockade is lack of intratumoral T cells.6,7 Therefore, combination with agents that remodel an immunosuppressive tumor environment and recruit T cells to the tumor could alleviate this issue. Furthermore, in line with the physiological role of PD-1/PD-L1 in maintenance of immunological self-tolerance, autoimmune adverse events are frequently observed upon systemic treatment with immune checkpoint blocking antibodies.8

Oncolytic viruses (OV) are gaining clinical relevance as a modality of cancer immunotherapy. OVs exert therapeutic activity by specifically infecting and destroying malignant cells and by activating anti-tumor immune responses. OV infection induces an acute inflammation
Figure 1. MeVac encoding antibodies against murine PD-1 and PD-L1

(A) Vector design. Schematic of MeVac vectors encoding the respective transgenes (T). Transgene cassettes include a Kozak sequence, mouse immunoglobulin κ secretion signal, HA and myc tags for detection, and the respective light and heavy chains of antibodies targeting murine PD-1 and PD-L1 connected by a glycine-serine linker. Transgene cassettes including the respective Fc fragments only were used for controls. To target murine MC38cea tumors, the natural tropism of the MeVac vectors was modified by fusing a single chain variable fragment of a CEA-specific antibody to “blinded” measles H with mutations in the receptor binding sites (Hbl-αCEA). N, P, M, F, and L, genes encoding measles structural proteins; ld, measles virus leader; tr, measles virus trailer. (B) Replication kinetics. MC38cea cells were infected with MeVac vectors encoding the respective transgenes at a multiplicity of infection (MOI) of 3. Triplicate samples were pooled, and viral progeny at designated time points were determined by titration assay in cell infectious units (ciu) per milliliter cell culture supernatant. Mean values of quadruplicates are shown. Error bars indicate SD. (C) Cell viability. MC38cea cells were infected with MeVac vectors encoding the respective transgenes at MOI = 5. Cell viability was determined using XTT assay at the depicted time points. Results are

(legend continued on next page)
within the tumor and provides pathogen- and danger-associated molecular patterns. Death of OV-infected tumor cells releases tumor-associated antigens (TAAs) in this immunostimulatory context, thereby promoting immune cell influx, anti-tumor immune responses and remodeling of the tumor immune environment. 1 During OV infection, expression of peripheral immune checkpoint molecules PD-L1 and PD-1 is also upregulated, creating a potential resistance to the therapy.15,16 Thus, OV therapy and PD-1/PD-L1 blockade may complement and potentiate each other by synergistic mechanisms of action. Combination therapy may increase the range of responsive tumors, as each therapy would target a resistance factor of the other. Multiple studies have demonstrated that combination of an oncolytic virus and PD-1/PD-L1 blockade provides therapeutic benefits.10–14 A phase Ib clinical study combining intratumoral injections of the clinically approved OV talimogene laherparepvec (T-VEC) and systemic administration of pembrolizumab demonstrated that the combination is well tolerated and provides high overall and complete response rates in advanced melanoma.15 Correlative research indicated that T-VEC therapy remodels the tumor environment in favor of further PD-1 blockade.16 Several variables affect the efficacy of a combination therapy regimen, including the sequencing schedule of the therapies, choice of the specific PD-1/PD-L1 antibody, and choice of OV platform. At least ten different OV platforms have been investigated as potential partners for PD-1/PD-L1 blockade in pre-clinical and clinical studies.17 Currently there are insufficient data to ascertain which combination strategy provides optimal efficacy.

Among these OV platforms, oncolytic measles virus (MV) vectors, based on attenuated measles vaccine strain viruses, are characterized by their solid safety record, efficacious cytokotoxicity mechanism, and versatility. Numerous pre-clinical studies18 and early clinical data19–23 indicate efficacy against a range of tumor entities. The MV vector platform can be used to encode large transgenes, including monoclonal antibodies.18 We have previously demonstrated that oncolytic MV encoding anti-human/murine-PD-L1 (atezolizumab) provides higher therapeutic efficacy in pre-clinical murine tumor models in comparison with control MV vectors.12,24

In this study we aimed to investigate options for the combination of oncolytic MV vectors with PD-1/PD-L1 blockade in more detail. Using the MV Schwarz vaccine platform (MeVac), we developed novel vectors encoding PD-1 blocking vector. Furthermore, we assessed whether the combination of oncolytic MeVac with systemically or vector-encoded PD-1/PD-L1 check-point blockade was more effective. Correlative analyses indicated a more robust T cell memory response by the combination of MeVac and PD-1/PD-L1 blockade compared with MeVac alone. On the basis of our results, we developed MeVac vectors encoding the clinically approved PD-1 blocking antibodies nivolumab and pembrolizumab.

RESULTS

Tumor cell expression of PD-L1 after oncolytic measles virus treatment

Studies from our and other groups had previously reported upregulation of PD-L1 upon virotherapy.12,25,26 We confirmed this finding in murine tumor cell lines. 48h after inoculation with MeVac, B16-CD46 melanoma and MC38-CD46 colorectal adenocarcinoma cells showed upregulation of PD-L1 compared with mock infected controls (Figure S1). Upregulation of PD-L1 upon virotherapy may sensitize tumors to PD-1/PD-L1 checkpoint blockade or represent a possible resistance mechanism. Therefore, this finding provides a rationale for testing the combination of virotherapy with PD-1/PD-L1 checkpoint blockade.

Generation and in vitro characterization of a novel MeVac vector encoding an antibody against murine PD-1

We have previously described a MeVac vector encoding an antibody against murine and human PD-L1, MeVac zmPD-L1, wherein the antibody sequence corresponds to the clinically used agent atezolizumab.12 In analogy to this vector, we generated a vector encoding an antibody against murine PD-1, MeVac zmPD-1. The cassettes for zmPD-1 and zmPD-L1 consist of the light and heavy chains of the respective antibodies linked by a glycine-serine linker, preceded by a Kozak sequence and an Igk leader sequence as a secretion signal. HA and myc tags are included in the constructs for detection and purification of the encoded antibodies (Figure 1A). The anti-PD-L1 antibody is of human IgG1 subtype, which can interact with murine Fc receptors and mediate antibody-dependent cellular cytotoxicity (ADCC).27 The novel zmPD-1 construct encompasses an Fc region from Syrian hamster (Cricetulus migratorius [C.m.]), corresponding to the antibody used for systemic PD-1 blockade. As controls, vectors encoding the respective Fc regions only were generated (MeVac IgG1-Fc and MeVac IgG-Fc C.m.).

Cassettes encoding the transgenes were inserted into the MeVac genome downstream of the MeVac hemagglutinin (H) open reading frame, as depicted in Figure 1A. Murine cells are not susceptible to MeVac, because of the lack of the respective cell entry receptors. To allow investigation of these vectors in the established murine
MC38cea model of measles virotherapy, the MeVac H attachment protein was fused to a single chain variable fragment of an antibody against human carcinoembryonic antigen (CEA).

We compared the characteristics of the novel MeVac vectors encoding zmPD-1 and IgG-Fc C.m. with the existing constructs encoding zmPD-L1 and IgG1-Fc. Replication kinetics and cytotoxic properties in MC38cea cells as assessed by one-step growth curves and cell viability assays (Figures 1B and 1C) show similar kinetics between the different constructs. However, MeVac zmPD-1 was attenuated compared with the respective control vector, MeVac IgG Fc C.m., as indicated by a more than 1 log difference in viral progeny. Secretion of zmPD-1 and zmPD-L1 after infection of MC38cea and Vero-αHis cells with the recombinant MeVac vectors was confirmed by western blot (Figures 1D, 1E, and S2). Kinetics of transgene expression were analyzed using western blot (Figure S2). High amounts of transgene product were present in input virus suspensions (time point 0 h post-infection [p.i.]). Nevertheless, these results indicate de novo synthesis of zmPD-1, zmPD-L1, IgG-Fc C.m., and IgG1-Fc, with peaks at 72 h p.i. (for zmPD-1), 24–48 h p.i. (for IgG-Fc C.m.), and 48 h p.i. (for zmPD-L1 and IgG1-Fc).

zmPD-1 and zmPD-L1 secreted from infected cells were shown to bind PD-1-positive murine cytotoxic T cells (CTL-ova) and PD-L1-positive tumor cells, respectively (Figures 1F and 1G). Specific binding to PD-1 and PD-L1, respectively, was confirmed by competitive binding assays (Figure S3). Functionality of MeVac-encoded zmPD-L1 has also been reported previously.

Therapeutic efficacy of intratumoral MeVac zmPD-1 in comparison with combination of intratumoral MeVac and systemic zmPD-1

We compared the efficacy of the novel MeVac zmPD-1 to a combination of systemic delivery of zmPD-1 and intratumoral (i.t.) therapy with MeVac IgG-Fc C.m. and to each of the monotherapies (MeVac IgG-Fc C.m. i.t. and zmPD-1 only). We tested these therapeutic strategies in the murine colorectal adenocarcinoma model MC38cea, which is syngeneic to C57BL/6 mice. MC38cea cells were implanted subcutaneously (s.c.) into the right flank of mice. After tumor establishment, mice were treated with i.t. injections of MeVac variants on 4 consecutive days according to the experimental schedule in Figure 2A. MeVac IgG-Fc C.m. was used as a control vector in the MeVac i.t.-only group and in the combination group of MeVac i.t. with systemic zmPD-1. In the groups that received systemic antibody treatment, intraperitoneal (i.p.) injections with the antibody were initiated on day 6 after implantation of the tumor cells and continued every third day for a total of four injections (Figure 2A). Intraperitoneal injections of zmPD-1 only did not significantly improve survival in comparison with mock treatment (Figure 2B), although there was a slight delay in tumor progression in individual animals in the zmPD-1 i.p. group (Figures 2C and 2D). In both MeVac IgG-Fc C.m. treatment groups, survival of the animals was significantly improved in comparison with mock treatment (Figure 2B). There were no statistically significant differences between the treatment groups that received MeVac in any of the tested regimens. Several mice in the MeVac treatment groups showed complete tumor remissions (CRs), distributed as follows: five CRs in the MeVac IgG-Fc C.m. i.t. and zmPD-1 i.p. combination group, four CRs in the MeVac zmPD-1 i.t. group, and three CRs in the MeVac IgG-Fc C.m. i.t. only group (Figure 2B).

Analysis of the relative tumor volume changes of individual mice (Figures 2C–2G) shows that for most of the mice experiencing CRs in the MeVac IgG-Fc C.m. i.t. and zmPD-1 i.p. combination group, a sharp increase in tumor volume occurred in the first 3 days following the MeVac IgG-Fc C.m. i.t. injections before a rapid decrease of tumor volume (Figure 2F).

To assess the safety of administering systemic versus MeVac-encoded PD-1 checkpoint blockade, we measured zmPD-1 levels in sera after treatment with zmPD-1 intravenously (i.v.), zmPD-1 i.p., or MeVac zmPD-1 i.t. (Figure S4). Sera were tested positive for zmPD-1 after systemic (i.v. or i.p.) dosing. In contrast, despite detecting MeVac mRNA within tumors, we did not detect zmPD-1 in mouse sera after treatment with MeVac zmPD-1. Having demonstrated comparable efficacy and potentially improved safety, we further pursued i.t. MeVac zmPD-1 as an approach for combination of measles virotherapy and PD-1/PD-L1 checkpoint blockade.

Therapeutic efficacy of MeVac zmPD-1 and MeVac zmPD-L1

Next we assessed therapeutic efficacy of the novel MeVac zmPD-1 vector compared with the previously developed MeVac zmPD-L1 in the subcutaneous MC38cea tumor model (Figures 3 and S5), as outlined in Figure 3A. MeVac IgG-Fc C.m. and MeVac IgG1-Fc were used as controls. Treatment with MeVac vectors significantly delayed tumor growth and prolonged survival of the animals in comparison with mock treatment (Figures 3B–3G and S5B–S5G).

When treatment was initiated on day 4 after tumor implantation (as in the experiment presented in Figure 2), four of ten mice in the MeVac IgG-Fc C.m., MeVac IgG1-Fc, and MeVac zmPD-1 groups and five of ten mice in MeVac zmPD-L1 group experienced CRs (Figure 3).

In a second experiment, treatment was initiated on day 5 after tumor implantation (Figure S5A). In this case, there were no CRs in the MeVac IgG-Fc C.m. and MeVac IgG1-Fc control groups, while two of ten and three of ten mice had CRs in the MeVac zmPD-L1 and MeVac zmPD-1 groups, respectively (Figure S5B).

Analysis of the relative tumor volume changes of individual mice showed that in most animals in both experiments, there was an initial decrease in tumor volume following treatment with any of the MeVac variants (Figures 3C–3G and S5C–S5G). Afterward, in several animals this decrease in tumor volume continued and resulted in complete tumor remissions, while in others tumor growth resumed. In one experiment in the group receiving treatment with MeVac zmPD-L1, tumor growth was delayed longer in more animals than
in the groups receiving treatment with the other MeVac constructs (Figure 3E).

**Tumor immune environment following MeVac zmPD-1 or MeVac zmPD-L1 therapy**

We further aimed to analyze changes in the tumor immune environment following treatment with MeVac zmPD-1 or MeVac zmPD-L1. As in previous experiments with MeVac zmPD-L1,14 we used the s.c. MC38cea tumor model and collected tumor samples for analysis 4 days after the last treatment (Figure 4A). First, we analyzed changes in the levels of seven different intratumoral cytokines. The results showed a trend toward increased IFN-γ and TNF-α levels in tumors following therapy with MeVac zmPD-L1 or MeVac zmPD-1 in comparison with mock treatment, while in the MeVac IgG1-Fc and MeVac IgG-Fc C.m. groups, the levels of these cytokines remained comparable with mock (Figures 4B and 4C). We did not detect any meaningful changes in the levels of interleukin (IL)-6, IL-2, IL-10, IL-17, and IL-4. Furthermore, we analyzed intratumoral T and NK cell populations following MeVac therapy by flow cytometry. The gating strategy is shown in Figure S6. We observed an increase in the intratumoral CD8+ T cell population following treatment with all MeVac constructs. A trend toward a higher abundance of CD8+ cells in tumors following treatment with MeVac zmPD-L1 compared with MeVac zmPD-1 was observed (Figure 4D), but the same was not observed for MeVac zmPD-1 and the respective control vector (Figure 4E). Also, an increase in the abundance of intratumoral CD4+ cells was observed following treatment with MeVac zmPD-L1 and MeVac IgG1-Fc in comparison with mock, with a trend toward a higher abundance of CD4+ cells in the MeVac zmPD-L1 group (Figure 4F). No statistically significant differences in the CD4+ cell population were observed in the experiment assessing MeVac zmPD-1 (Figure 4G). The NK cell population (CD335+) was significantly reduced in the MeVac zmPD-L1 group in comparison with mock, while there were no differences among all the other analyzed groups (Figures S7A and S7B). We further determined expression of the early activation marker CD69 on the surface of intratumoral CD8+, CD4+, and NK cells following the different treatments. We observed significantly smaller CD8+CD69+ and CD4+CD69+ populations following treatment with MeVac zmPD-L1 and MeVac IgG1-Fc in comparison with the mock group (Figures 4H and 4J). A trend toward smaller CD8+CD69+ and CD4+CD69+ populations was also observed following treatment with MeVac zmPD-1 and MeVac IgG-Fc C.m. compared with the mock group, although the differences between the mock and MeVac IgG-Fc C.m. groups were not significant (Figures 4I and 4K). The CD4+CD69+ population was reduced in three tumors treated with MeVac zmPD-1, although no significant differences in comparison with mock and MeVac IgG-Fc C.m. treatment groups were observed when considering all tumor samples.
No significant changes in CD69 expression were observed in the CD335+ NK cell population, although there was a trend toward a smaller CD69+ population in the group receiving MeVac a mPD-1 (Figures S7C and S7D).

Tumor-specific immune memory following treatment with MeVac

We further assessed establishment of a long-term anti-tumor immune response in animals that experienced complete tumor remissions after treatment with MeVac vectors (experiments shown in Figures 3 and S5). To this end, MC38 cells were implanted s.c. in the flank contralateral to the primary tumor, and regrowth of secondary tumors was monitored. Tumor regrowth after implantation was observed in five of six naive animals. In contrast, all of the animals that previously experienced complete tumor remissions rejected secondary tumor engraftment in MeVac a mPD-1 and MeVac a mPD-L1 groups in comparison with naive animals and animals from MeVac IgG Fc C.m. and MeVac IgG1-Fc control groups (Figure 5B), suggesting a more robust anti-tumor immune memory response.

Memory T cell populations following MeVac a mPD-1 therapy

Following the observation of increased IFN-γ recall response after MeVac a mPD-1 and MeVac a mPD-L1 treatment, we further investigated the impact of MeVac a mPD-1 therapy on the memory T cell population. We analyzed expression of the markers CD44 and CD62L on CD8+ and CD4+ T cells to investigate changes in the functional subsets of memory T cells in tumors and in tumor-draining lymph nodes (TDLNs) 4 days after the last treatment by flow cytometry. The gating strategy is shown in Figure S8.

In tumors we observed a significantly higher ratio of effector memory (EM) (CD44+CD62L–) to central memory (CM) T cells (CD44+CD62L+) among both CD8+ and CD4+ T cell populations following treatment with MeVac IgG1-Fc C.m. and MeVac a mPD-1 in comparison with mock (Figures 5C and 5D). A trend toward a larger intratumoral EM/CM ratio of CD4+ T cells in comparison with the MeVac IgG-Fc C.m. group was observed in the MeVac a mPD-1 group, with considerable variation among individual mice.

In TDLNs there was no significant difference in the ratio of EM to CM T cells between treatment groups (Figures 5E and 5F). However, there was a relative decrease in CM and relative increase in EM T cells after treatment with MeVac a mPD-1 (not shown).

MeVac encoding pembrolizumab, nivolumab, or atezolizumab

In addition to MeVac encoding the anti-PD-L1 antibody atezolizumab,24 we generated MeVac vectors encoding the clinically approved...
anti-PD-1 antibodies pembrolizumab and nivolumab. In analogy to a previously described adeno-associated viral (AAV) vector,55 transgene cassettes constituting a Kozak sequence, Igκ leader, and the respective antibody heavy and light chains separated by an F2A linker were inserted downstream of the MeVac H gene (Figure 6A). MeVac encoding human IgG4 Fc only was generated as a control vector. Replication kinetics of the novel vectors were analyzed in Vero cells and the human colorectal adenocarcinoma cell lines Colo 205 and HT-29 (Figure 6B). ELISA of infected cell supernatants revealed secretion of pembrolizumab and nivolumab after inoculation with the respective recombinant MeVac vectors (Figure 6C). Interestingly, nivolumab appeared to be expressed at higher levels. Binding of pembrolizumab and nivolumab secreted from cells infected with the respective vectors to PD-1+ human immune cells was confirmed using flow cytometry (Figure 6D). As demonstrated previously, atezolizumab secreted from cells infected with MeVac encoding this anti-PD-L1 antibody bound to PD-L1+ human colorectal cancer cells (Figure S9).

Figure 4. Immunomodulatory effects of MeVac amPD-1 and MeVac amPD-L1
(A) MC38cea cells were implanted subcutaneously into the right flanks of C57BL/6J mice. Treatment was initiated when the average tumor volume reached 100 mm³ (n = 9–12 per group). Animals received intratumoral injections with 1 × 10⁶ cell infectious units of MeVac vectors encoding the respective transgenes on four consecutive days. Animals in the mock group received i.t. injections of OptiMEM. Animals were sacrificed and tumors were explanted 4 days after the last treatment. (B and C) Protein extraction was performed from a sample of each of the explanted tumors, and cytokine bead array was performed to measure intratumoral concentrations of seven different cytokines. Box-and-whisker plots with whiskers depicting minimal and maximal detected concentrations as well as median in each group are shown. (D–K) Samples from each of the explanted tumors were prepared for flow cytometry analysis. The percentages of cytotoxic T cells (CD8⁺), T helper cells (CD4⁺), activated cytotoxic (CD8⁺ CD69⁺), and helper (CD4⁺ CD69⁺) T cells among leukocytes (CD45⁺) were determined. Dots representing individual tumors and bars representing the median in the group are shown. Data were analyzed using one-way ANOVA with Dunn’s multiple-comparisons post hoc test.
To test whether MeVac-encoded anti-human PD-1 antibodies can re-invigorate T cells, we stimulated peripheral blood mononuclear cells (PBMCs) with varying concentrations of *Staphylococcus* enterotoxin B (SEB) and added supernatants from cells infected with MeVac encoding pembrolizumab, nivolumab, or IgG4. Supernatants from cells infected with MeVac encoding pembrolizumab or nivolumab elicited increased levels of interleukin-2 secretion, indicating T cell activation (Figure 6E). Interestingly, MeVac pembrolizumab samples elicited higher IL-2 levels after 40 h of incubation, while MeVac nivolumab samples elicited higher IL-2 levels after 70 h of incubation.

**DISCUSSION**

Immune checkpoint blockade targeting the PD-1/PD-L1 axis is a pillar of many successful treatment strategies. Various combination treatments including anti-PD-1 and anti-PD-L1 antibodies are currently investigated in clinical trials. Oncolytic viruses are appealing combination therapeutics for cancer immunotherapy that induce immunogenic tumor cell death and promote tumor-specific T cell responses. Supporting this notion, combination of the FDA-approved oncolytic herpes virus talimogene laherparepvec with pembrolizumab has achieved remarkable response rates in advanced melanoma. Instead of combination treatment, encoding checkpoint blocking antibodies within an oncolytic vector has the benefit of increasing local concentrations at the tumor site while decreasing systemic exposure, thereby optimizing the therapeutic index. This concept of encoding PD-1/PD-L1 antibodies has been adopted to various oncolytic platforms, including adenovirus and herpes virus. We have previously described oncolytic measles viruses encoding antibodies against PD-L1 and tested their efficacy in the MC38cea model. Here, we report the generation and assessment of oncolytic measles vaccine vectors encoding antibodies against mouse and human PD-1. Overall, we observed a modest benefit of combining PD-1/PD-L1 checkpoint blockade with oncolytic measles virus in the MC38cea model, although this tumor displays features generally associated with response to PD-1/PD-L1 checkpoint blockade: MC38cea has a high mutational load and shows PD-L1 expression, which is further upregulated upon MeVac treatment (Figure S1).
Figure 6. MeVac vectors encoding pembrolizumab and nivolumab

(A) Vector design. Schematic of MeVac vectors encoding the respective transgenes (T). Transgene cassettes include a Kozak sequence, mouse immunoglobulin κ secretion signal, and (I) the respective light and heavy chains of pembrolizumab or nivolumab connected by an F2A linker or (II) the human IgG4 Fc region. (B and C) Replication kinetics and transgene expression. Simian Vero as well as human colorectal carcinoma Colo 205 and HT-29 cells were infected with indicated MeVac variants at MOI = 3. (B) Viral progeny were determined at designated time points by serial dilution titration assay. Mean values of quadruplicates and SDs are shown. (C) Concentrations of nivolumab and pembrolizumab in cell culture supernatants were determined using ELISA. (D) Binding of MeVac-encoded pembrolizumab or nivolumab to PD-1+ human immune cells. Peripheral blood mononuclear cells (PBMCs) from healthy donors were stimulated with PMA and ionomycin, which induces PD-1 expression. Stimulated PBMCs were incubated with supernatants from Vero cells infected with MeVac encoding IgG4, pembrolizumab, or nivolumab and stained with a PE-labeled antibody specific for human IgG-Fc. Data from three independent experiments were analyzed using one-way ANOVA with Tukey’s multiple-comparisons test. (E) Functional assay for pembrolizumab and nivolumab. Human PBMCs were stimulated with SEB and incubated with supernatants from Vero cells infected with MeVac encoding pembrolizumab, nivolumab, or IgG4-Fc. After 40 and 70 h, IL-2 concentration in PBMC culture supernatants was determined using ELISA. Results were analyzed using two-way ANOVA with Tukey’s multiple-comparisons test.
However, murine tumors show limited permissiveness for measles virus, thus limiting the levels of antibody expression (Figures 1B, 1C, and S2B). Moreover, different PD-1 antibody clones may yield different outcomes. There is an ongoing debate regarding which PD-1 clone and Fc fragment is optimal to block inhibitory signals without depleting tumor-reactive effectors cells.37,38

In this regard, pre-clinical mouse models with xenogeneic antibodies do not recapitulate clinically applied anti-PD-1/PD-L1, limiting the transferability to clinical treatment settings.39 In contrast to murine tumors, we observed high levels of pembrolizumab and nivolumab secretion from human cancer cells infected with the respective MeVac vectors (Figure 6). Thus, we would expect stronger effects against human tumors.

We observed no significant differences in efficacy of the MeVac-encoded anti-PD-1 compared with the combination of MeVac with systemic anti-PD-1 (Figure 2B). This is in line with our previous findings in a different murine tumor model (B16 melanoma), in which an oncolytic measles vaccine virus (Edmonston B-derived) encoding anti-PD-L1 showed similar efficacy as the combination of virus and systemic PD-L1 antibody.12 PD-1 blockade has been found to also act in tumor-draining lymph nodes.40 In line with previous studies with C57BL/6 mice,42 we did not detect MeVac mRNA in TDLN (data not shown). However, as the TDLN have been shown to play an essential role in response to PD-1/PD-L1 checkpoint blockade in the MC38 model,40 we assume that effects of intratumorally administered MeVac vectors may extend to the TDLNs via recirculating immune cells.

Analyses of the tumor immune environment revealed subtle changes upon MeVac-mediated PD-1/PD-L1 checkpoint blockade. Of note, oncolytic measles virotherapy alone (i.e., treatment with MeVac IgG1-Fc) already leads to activation of innate and adaptive immunity in the MC38eca model, as shown by previously published gene expression profiling.43 Tumors that are less responsive to MeVac alone may show more added benefit of combination with PD-1/PD-L1 checkpoint blockade. This notion is supported by data from other models of measles virus oncolysis.12,43,44 In tumor samples, we observed an increase in inflammatory effector cytokines after treatment with MeVac, which was enhanced with vectors encoding PD-1/PD-L1 antibodies (Figures 4B and 4C). In individual mice, an initial increase in tumor volume was observed before tumor regression. This may be attributable to acute intratumoral inflammation upon virotherapy or perhaps resemble the clinical phenomenon of pseudoprogression during cancer immunotherapies,45 although kinetics differ from clinical settings in this rapidly progressing transplantable mouse tumor model.

We found slight changes in the intratumoral and TDLN T cell compartments upon MeVac zPD-1/PD-L1 treatment. Although there was a trend toward increased overall abundance of both intratumoral CD8+ and CD4+ T cells, we observed a decrease in T cells expressing the early activation marker CD69 (Figures 4D–4K). This may be explained by a shift toward a T cell effector memory phenotype (Figures 5C–5F). As NK cell activation has been implicated in PD-1/PD-L1 checkpoint blockade,46 we also analyzed this subset of tumor-infiltrating immune cells but found no significant changes in their abundance or activation status. Longitudinal analyses including in-depth phenotyping across multiple time points could provide insights into the dynamics of the tumor immune environment. These results could pinpoint effector mechanisms involved in response and also possible resistance factors such as oncogenic signaling, myeloid-derived suppressor cells, or alternative immune checkpoints limiting response to PD-1/PD-L1 checkpoint blockade.47 These factors could be targeted by alterations of the treatment regimen, including additional modifications of MeVac vectors. Toward this end, oncolytic measles vaccine viruses provide a flexible platform to develop safe immunotherapeutic vectors.18 Several immunotherapeutic strategies have been implemented using this platform that could be adopted in this context. In case insufficient T cell effector functions are identified as limiting MeVac zPD-1/PD-L1 therapy, interleukin-12 could be incorporated.44 If tumor cell recognition is deemed insufficient, bispecific T cell engagers (BiTEs) could be encoded in the vector. Our previous results suggested benefits from combining oncolytic measles viruses encoding BiTEs with immune checkpoint blockade.48 Other resistance mechanisms such as pro-tumorigenic signaling or myeloid-derived suppressor cells47,49,50 could also be addressed using advanced oncolytic vectors.

Importantly, despite limited effects of MeVac-encoded zmPD-1 and zmPD-L1 on the immediate treatment response, we did detect protective immune memory and an enhanced tumor-specific memory recall response after treatment with MeVac zmPD-1 and MeVac zmPD-L1.

The vectors we developed, which encode the clinically approved PD-1 blocking antibodies pembrolizumab and nivolumab, could provide benefits in this regard. We therefore envision this therapeutic approach in a setting with minimal residual disease. In such a scenario, MeVac encoding anti-PD-1/PD-L1 could be used to lyse remaining tumor cells and induce anti-tumor immunity via oncolytic vaccination effects, which are then consolidated into long-term protective anti-tumor memory responses.

MATERIALS AND METHODS

Cell lines

The African green monkey kidney cell line Vero was obtained from the American Type Culture Collection (CCL-81). The Vero-zHis cell line stably expressing a single chain antibody against His6 tag was a gift from S. J. Russell (Mayo Clinic, Rochester, MN). The murine colorectal adenocarcinoma cell line MC38 and the MC38 cell line transduced for stable expression of a human CEA (MC38eca45) were obtained from R. Cattaneo (Mayo Clinic). The cell line Colo 205 (CCL-222) was obtained from A. Jassowicz (Deutsches Krebsforschungszentrum [DKFZ], Heidelberg, Germany). The cell line HT-29 (HTB-38) was obtained from C. Plass (DKFZ). B16-CD46 and MC38-CD46 cells stably expressing human CD46 were generated
as described previously.\textsuperscript{48} Vero, Vero–zHis, MC38, MC38-CD46, and MC38cea cells were cultivated in Dulbecco’s modified Eagle’s medium (DMEM) (3196604; Life Technologies) supplemented with 10% fetal calf serum (FCS) (FB-1000/500 [Biousera, Nuillé, France] and FBS Good [Pan-Biotech, Aidnach, Germany]). B16-CD46, Colo 205, and HT-29 cell lines were maintained in Roswell Park Memorial Institute (RPMI) 1640 medium (61870044; Life Technologies) with 10% FCS. The CTL-ova cell line has been described previously.\textsuperscript{73} CTL-ova cells were provided by S. Eichmüller and W. Osen (DKFZ) and cultivated in α-MEM medium (Sigma-Aldrich, Taufkirchen, Germany) supplemented with 10% FCS, 4 mM L-glutamine, 100 U/ml penicillin, 100 μg/ml streptomycin, and 10 μM β-mercaptoethanol (all from Thermo Fisher Scientific, Schwerte, Germany) and re-stimulated as described before.\textsuperscript{34} All cell lines were cultivated at 37°C in a humidified atmosphere with 5% CO₂. Routine tests for mycoplasma contamination were performed.

**Cloning and generation of recombinant MeVac**

MeVac eGFP, cloning of MeVac encoding an antibody against murine/human PD-L1 (MeVac zmPD-L1; antibody sequence corresponds to clinically used atezolizumab), and MeVac encoding the antibody constant region IgG1-Fc (MeVac IgG1-Fc) have been described previously.\textsuperscript{34} The cassette encoding an antibody against murine PD-1 (zmPD-1) was designed in analogy to the existing anti-murine/human-PD-L1 construct. In contrast to the zmPD-1 (aterolizumab) cassette, in which the constant region corresponds to human IgG1-Fc, in the novel zmPD-1 construct we used hamster (Cricetulus migratorius) IgG-Fc (IgG-Fc C.m.). The zmPD-1 corresponds to clone J43, which is of C.m. origin. The zmPD-1 cassette consists of the following elements: a Kozak sequence, the Igk leader sequence, an HA tag, the variable light chain sequence of J43, a Gly-Ser linker, the variable heavy-chain sequence of J43, the Fc region of the antibody, and a myc tag. To comply with the “rule of six,”\textsuperscript{35} a TA spacer was inserted at the 3’ end of the construct. GEN-Eus codon optimization for expression in murine cells was performed to obtain the final sequence (Eurofins MWG Operon, Ebersberg, Germany). The cassette encoding IgG-Fc C.m. was designed similarly and consisted of a Kozak sequence, the Igk leader sequence, an HA tag, the IgG-Fc C.m. sequence, and a myc tag. Both zmPD-1 and IgG-Fc C.m. cassettes were flanked by MluI and Ascl restriction sites. After restriction digest with MluI and Ascl, the zmPD-1 (1,914 bp) or the IgG-Fc C.m. (1,182 bp) cassette was inserted into the additional transcription unit (ATU) downstream of the MeVac H gene via the unique MauBI site, yielding MeVac zmPD-1 or MeVac IgG-Fc C.m. In MeVac zmPD-L1, MeVac IgG1-Fc, MeVac zmPD-1, and MeVac IgG-Fc C.m. the MeVac H protein was fully retargeted to human CEA as described previously\textsuperscript{28} to allow infection of murine MC38cea cells.

The cassette encoding the nivolumab construct has been described previously.\textsuperscript{30} For insertion into the MeVac genome, the nivolumab cassette was generated by PCR using the existing construct as a template. The cassette encoding pembrolizumab was designed in analogy to the nivolumab construct. Both nivolumab and pembrolizumab constructs consist of the following elements: a Kozak sequence, an Igk leader sequence, and the open reading frame (ORF) of the variable heavy chain of the antibody followed by an F2A linker, an Igk leader sequence, and an ORF for the variable light chain of the antibody ending with an additional stop codon and a TA spacer to comply with the “rule of six” after insertion into the MeVac genome. The sequence of the novel pembrolizumab construct was optimized for Homo sapiens codon use with the GENEius codon optimization tool, and the final construct was obtained by gene synthesis (Eurofins MWG Operon). The IgG4-Fc construct consisting of a Kozak sequence, the Igk leader sequence, the IgG4-Fc sequence, and a TA spacer was generated by PCR using the nivolumab construct as a template. All final constructs were flanked by MluI and Ascl restriction sites. After restriction digest, the MluI-Ascl fragment containing the pembrolizumab (2,208 bp), nivolumab (2,172 bp), or IgG4-Fc (768 bp) cassette was inserted into an ATU downstream of the MeVac H gene via the unique MauBI site, yielding MeVac pembrolizumab, MeVac nivolumab, or MeVac IgG4-Fc.

Infectious viruses were obtained from the cDNA constructs using the reverse genetics system originally described by Radecke et al.,\textsuperscript{36} which was later adapted for RNA polymerase II.\textsuperscript{37} The detailed method to obtain viral particles from the generated antigenic constructs of recombinant MeVac vectors has been described previously.\textsuperscript{28}

**MeVac propagation, titration, and in vitro infection experiments**

Procedures for propagation and titration of recombinant measles vectors have been described in detail previously.\textsuperscript{23} In brief, for propagation, Vero or Vero–zHis cells were inoculated with MeVac at a multiplicity of infection (MOI) of 0.03 in OptiMEM. After 2–3 h the inoculum was removed, DMEM + 10% FCS was added onto the cell layer, and cultivation was continued. When syncytia had spread across the entire cell layer, the cells were scraped, harvested, and snap-frozen in liquid nitrogen. The collected samples were thawed and centrifuged at 2,500 × g for 5 min to remove cell debris, and the cleared supernatants were aliquoted and stored at −80°C. Viral titers were determined by performing 1:10 serial dilution titration assays on Vero or Vero–zHis cells in 96-well flat-bottom plates in octuplicates per dilution. The concentration of viral cell infectious units per milliliter (ciu/mL) was calculated by multiplying the average count of single syncytia per well per dilution 48 or 72 h post-infection with the respective dilution factor.

For in vitro infection experiments, the respective cells were seeded 1 day before inoculation. Inoculation with MeVac at the indicated MOI was performed in OptiMEM. The inoculum was removed after 2–3 h of cultivation, the cell line-specific medium was added, and cultivation was continued. Cell viability assays were performed with the Colorimetric Cell Viability Kit III (2,3-bis-[2-methoxy-4-nitro-5-sulphophenyl]-2H-tetrazolium-5-carboxanilide [XTT]) (Promo-Kine, Heidelberg, Germany).
Western blot for zmPD-1 and IgG-Fc C.m.

Vero-2His and MC38cea cells were seeded in 10 cm tissue culture plates and infected with MeVac zmPD-1 or MeVac IgG-Fc C.m. at MOI = 3. Supernatants from the infected plates (volume ~ 12 mL) were collected at 0, 10, 24, 48, 72, and 96 h post-infection (from one plate per time point), snap-frozen in liquid N₂, and stored at −80°C until further processing. The samples were thawed in a water bath at 37°C and sterile filtrated through a 0.2 μm filter. Afterward, immunoprecipitation was performed using Sepharose A beads (Biocat, Heidelberg, Germany). Sepharose A beads were washed three times with D-PBS (20 μL beads per sample) and after resuspension in D-PBS, beads were added to each sample. The samples were incubated for 1 h with rotation at room temperature (RT). After incubation, the beads were spun down for 3 min at 100 × g, washed twice with D-PBS, and resuspended in D-PBS. For denaturation, samples were diluted with 1 × Laemmli buffer and incubated for 5 min at 95°C. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblot analysis were performed as described in detail previously:

Flow cytometry assay for binding of MeVac-encoded antibodies to target cells

Vero-z2His or Vero cells were seeded in 15 cm tissue culture plates and infected with MeVac zmPD-1, MeVac IgG-Fc C.m., MeVac zmPD-L1 or MeVac IgG1-Fc (Vero-z2His) or MeVac pembrolizumab, MeVac nivolumab, or MeVac IgG4-Fc (Vero) at MOI = 0.03. When syncytia had spread across the entire cell layer (~39 h post-infection for Vero-z2His infections and ~48 h post-infection for Vero infections), the entire supernatant from each plate was collected, snap-frozen in liquid N₂, and stored at −80°C until further use. The samples were thawed in a water bath at 37°C and sterile filtrated through a 0.2 μm filter. The supernatant from each plate (~15 mL) was subjected to concentration using Amicon Ultra-15 10K Centrifugal Filter Device (Merck Millipore, Darmstadt, Germany) for 20 min at 4,000 × g at RT. Then the filtrate that passed through the membrane was removed and 13 mL D-PBS was added to the concentrate, and centrifugation for 20 min at 4,000 × g at RT was repeated. The resulting concentrate (~300 μL) was collected for further use. To test binding of anti-PD-L1, 1 × 10⁶ MC38cea cells were incubated with the supernatant samples containing zmPD-L1 or IgG1-Fc. To test binding of PD-1 targeting antibodies, 2 × 10⁶ murine CTL-ova cells were incubated with the concentrated samples containing zmPD1 or IgG-Fc C.m., and 2 × 10⁶ human PBMCs (activated for 24 h with 5 nM PMA and 500 nM ionomycin) were added to samples containing pembrolizumab, nivolumab, or IgG4-Fc. The cells were incubated with the concentrates for 20 min at RT. The cells were then spun down for 5 min at 300 × g and resuspended in 100 μL D-PBS per sample. MC38cea and CTL-ova cells were stained with 10 μL PE anti-HA tag (Clone GG8-1F3.3.1) (Milltenyi Biotech, Bergisch-Gladbach, Germany). CTL-ova cells were also stained with 1 μL APC Rat Anti-Mouse CD8α (clone 53-6.7) (BD Biosciences, Heidelberg, Germany) per sample, human cells were stained with 5 μL anti-human IgG-Fc-PE (BioLegend, London, United Kingdom) per sample and incubated for 30 min at RT in the dark. For the experiment with murine cells, as a positive control, 1 × 10⁶ CTL-ova in 100 μL were stained with 1 μL PE anti-mouse CD279 (PD-1) (clone RMP1-30) (BioLegend) and 1 μL APC Rat Anti-Mouse CD8α (clone 53-6.7) (BD Biosciences) and incubated for 30 min at RT in the dark. Afterward, 1 mL D-PBS was added to each stained sample and centrifuged at 300 × g for 5 min at RT. Each cell pellet was resuspended in 500 μL D-PBS with 0.2 μg 4’6-diamidino-2-phenylindole (DAPI). Single stain and isotype controls were prepared using CTL-ova cells or freshly isolated human PBMCs in parallel to the samples and used for compensation and gating. The samples and controls were acquired on a BD FACS LSRII with FACSDiva software (version 8.0.1) and analyzed using FlowJo version 10.0.7r2 (Tree Star).

Competitive binding assays for anti-PD-1 and anti-PD-L1

Splenocytes from a 7-week-old C57BL/6 female mouse were cultured at 37°C and 5% CO₂ in non-treated six-well plates at 4 × 10⁶ cells per well in 2 mL RPMI-GlutaMAX supplemented with 10% FCS, 50 μM 2-mercaptoethanol (Thermo Fisher Scientific), 1% penicillin/streptomycin (Thermo Fisher Scientific), 10 ng/mL PMA (Sigma-Aldrich), and 500 ng/mL ionomycin (Cayman Chemical, Ann Arbor, MI). After 72 h, the cells were harvested and incubated for 30 min at 4°C with 10 μL cell lysate from Vero-z2His cells infected with MeVac zmPD-1 and 10 μL of 5-fold dilutions of a commercial zmPD-1 antibody (stock concentration of 1 mg/mL, clone J43; Thermo Fisher Scientific) as competitor. Cell lysate from Vero-z2His cells infected with MeVac IgG-Fc C.m. was used as a negative control.

MC38-CD46 cells and Colo 205 cells were seeded in six-well plates at 3 × 10⁵ cells per well and infected 24 h afterward with MeVac at MOI = 3 and MeVac eGFP at MOI = 0.03, respectively. 48 h after infection, the cells were harvested and incubated for 30 min at 4°C with 10 μL cell lysate from Vero-z2His cells infected with MeVac zmPD-L1 and 10 μL of 5-fold dilutions of commercial atezolizumab (stock concentration of 3.2 ng/mL; Heidelberg University Hospital Pharmacy, Heidelberg, Germany) as a competitor. Cell lysate from Vero-z2His cells infected with MeVac IgG1-Fc was used as a negative control.
Mouse splenocytes, MC38-CD46 cells, and Colo 205 cells incubated with the corresponding cell lysates were stained with a PE anti-HA tag antibody (clone GG8-1F3.3.1; Miltenyi Biotech) at a 1:50 dilution for 30 min at 4°C in the dark. DAPI (Sigma-Aldrich) was used as a viability dye. The samples and controls were acquired on a BD FACS Canto II flow cytometer (BD). Data were analyzed using the BD FACSDiva software and FlowJo software.

Animal experiments
All experimental procedures with animals were approved by the regional council (Regierungspräsidium Karlsruhe, protocols G-192/15 and G-58/17) and performed in compliance with the German Animal Protection Law and institutional guidelines. Six- to eight-week-old female C57BL/6J mice were acquired from Harlan Laboratories (Rossdorf, Germany). Mice were housed in groups of five in individually ventilated cages at the Center for Preclinical Research of the German Cancer Research Center.

MC38cea cells (1 × 10⁶) were subcutaneously implanted into the right flank of the animals in 100 μL total volume of D-PBS. When the average tumor volume reached approximately 50 mm³ (for survival experiments) or 100 mm³ (for analysis of tumor immune environment), the treatment was started according to the schedule of the respective experiment. For virus treatment, animals received intratumoral injections with 0.9 × 10⁶ or 1.0 × 10⁶ cfu of the respective MeVac construct in 100 μL. In the control groups of virus treatment, animals received i.t. injections with 100 μL of OptiMEM. For antibody treatment, animals received intraperitoneal injections with 100 μg of anti-mouse PD-1 (clone J43) antibody in 200 μL total volume. In control groups for antibody treatment, animals received i.p. injections with 200 μL D-PBS. Tumor growth was monitored by measuring the largest and smallest diameters of tumors every third day using a digital caliper. Tumor volume was calculated by using the formula largest diameter × smallest diameter² × 0.5.

In survival experiments animals were sacrificed when the tumor volume exceeded 1,000 mm³, the largest tumor diameter exceeded 15 mm, tumor ulceration occurred, or the animals were moribund. In the experiments for tumor immune environment analysis, the animals were sacrificed at the pre-defined time point of analysis. For tumor rechallenge experiments, 1 × 10⁵ MC38 cells were implanted into the left flank of the mice and tumor development was monitored every third day.

Cytokine bead array of tumor samples
Protein isolation from MC38cea tumor samples was performed as described previously. In brief, freshly collected tumor samples were transferred into empty 1.5 mL tubes, snap-frozen in liquid N₂, and stored at −80°C until processing. Samples were thawed on ice, minced using a scalpel, and homogenized using an Eppendorf-fitting pestle in lysis buffer consisting of 10 mM Tris-HCl (pH 8.0), 150 mM NaCl, 10% glycerol, 5 mM EDTA, 1% NP-40, and one Complete Mini, EDTA-free Protease Inhibitor Cocktail Tablet (Sigma-Aldrich). The obtained lysates were incubated for 1 h at 4°C with rotation. The samples were then sonicated at an intermittent (0.5 min) on and off sonication regimen for 7 min (high intensity) using a Diagenode Bioruptor R Standard with a cooling water pump (Diagenode, Seraing, Belgium). The lysates were cleared by centrifugation at 13,000 × g for 15 min, and supernatants were collected and stored at −80°C until analysis. Cytokine concentrations were measured using the Mouse Th1/Th2/Th17 Cytokine Bead Array Kit (BD Biosciences) according to the instructions of the manufacturer. For detection of virus-derived mRNA, tumor samples were collected in RNAlater (Thermo Fisher Scientific), and RNA was extracted using the RNeasy Mini Kit (Qiagen, Hilden, Germany). After reverse transcription using Maxima H Minus RT (Thermo Fisher Scientific) with Oligo(dT) primers, qPCR was performed using SYBRgreen (Thermo Fisher Scientific) on a BioRad CFXycler using the following primers:

- N-241 (5’→3’ TTACCACCTCGATCCAGACTTC)
- N-331+ (5’→3’ CCTATTAGTGCCCCCTGTAGTTT)

Flow cytometry of tumors and tumor-draining lymph nodes
Freshly explanted tumors or tumor-draining lymph nodes were transferred into appropriately sized tubes with D-PBS, stored on ice, and processed on the same day. The collected samples were minced in small pieces in RPMI-1640 + 10% FCS + 200 U/mL collagenase type I (Thermo Fisher Scientific), transferred into 50 mL tubes, and incubated at 37°C for 30 min with gentle vortexing every 10 min. The obtained suspensions were passed through 100 μm cell strainers, spun down at 300 × g for 5 min, and resuspended in 10 mL D-PBS. The cells were counted, and 2 × 10⁶ cells per sample were used for antibody staining in 100 μL D-PBS. For analysis of T and NK cell abundance and activation, the tumor samples were stained with fluorochrome-conjugated antibodies against the following murine lymphocyte markers: 1 μL CD45.2-PerCP-CyTM5.5 (clone 104), 1 μL CD4-APC-CyTM7 (clone GK1.5), 1 μL CD8a-APC (clone 53-6.7) (all from BD Biosciences), 1.25 μL CD69-PE (clone H1.2F3), and 2 μL CD335-FITC (clone 29A1.4) (both from BioLegend). For analysis of memory T cell populations, the tumor samples and tumor-draining lymph node samples were stained with following antibodies: 1 μL CD3-PerCP-CyTM5.5 (clone 17A2), 1 μL CD4-APC-CyTM7 (clone GK1.5), 1 μL CD8a-APC (clone 53-6.7) (all from BD Biosciences), 1 μL CD44-PE (clone IM7), and 1 μL CD62L-FITC (clone MEL-14) (both from BioLegend). After incubation in the dark for 30 min, 1 mL D-PBS was added per sample, and samples were spun down for 5 min at 300 × g. The pellets were resuspended in 500 μL D-PBS with 0.2 μg/mL DAPI. Directly afterward, the samples were acquired on a BD FACS LSR II (BD Biosciences). Data were analyzed using FlowJo software. Only samples with at least 1,000 cells were included in the analysis.

Tumor-specific IFN-γ restimulation assay
The detailed protocol for IFN-γ restimulation assay has been described previously. In brief, MC38 cells were resuspended in RPMI + 10% FCS + 1% penicillin/streptomycin + 20 U/mL IL-2 +
20 μg/mL mitomycin-C and incubated for 2 h with shaking at 37°C. Afterward, the cells were washed three times with D-PBS and resuspended in RPMI-1640 with 10% FCS, 1% penicillin/streptomycin, and 20 U/mL recombinant interleukin-2 (IL-2). In parallel, single-cell suspensions were prepared from freshly isolated murine spleens. The spleens were meshed through a 100 μm cell strainer (Neolab, Heidelberg, Germany) into 10 mL D-PBS. The obtained suspension was then centrifuged at 300 × g for 5 min at RT. The supernatant was discarded, and the cell pellet was resuspended in 1 mL ACK Lysing buffer (Thermo Fisher Scientific) and incubated for 10 min at RT. After the incubation, 9 mL D-PBS were added per sample and centrifuged at 300 × g for 5 min. The resulting pellet was resuspended in D-PBS, and cells were counted. Cocultures were prepared in RPMI-1640 + 10% FCS + 1% penicillin/streptomycin + 20 U/mL IL-2 using 1.7 × 10^5 MC38 tumor cells treated with mitomycin C and 5 × 10^6 splenocytes in a total volume of 1 mL in 24-well plates and incubated at 37°C and 5% CO_2. Medium was collected after 48 h and stored at −80°C until analysis. IFN-γ concentration was measured in the collected samples using an IFN-γ Mouse Uncoated ELISA Kit (Thermo Fisher Scientific).

**ELISA for zmPD-1, pembrolizumab, and nivolumab**

ELISA plates (Nunc Maxisorp) were coated with 100 ng per well recombinant mouse or human PD-1, His-tagged (Sinobiological, Beijing, China) overnight at 4°C. Wells were washed twice with D-PBS, and blocking buffer (PBS + 5% FCS + 0.05% Tween 20) was added for 2 h at RT. After washing three times with D-PBS, 100 μL samples were added for 2 h at RT. Following four washes with washing buffer (D-PBS + 0.05% Tween 20), 100 μL of diluted Biotin-coupled goat anti-hamster IgG (H + L) Secondary Antibody (Thermo Fisher Scientific; 1:20,000) in blocking buffer, for zmPD-1) or anti-human IgG4 antibody (Sigma-Aldrich; clone HP-6025, 1:60,000 in blocking buffer, for pembrolizumab and nivolumab) were added to each well and incubated for 1 h at RT. After five washing steps, 100 μL of diluted HRP-Streptavidin (Diaanova, Hamburg, Germany; 1:500) was added per well and incubated for 10 min at RT. Wells were washed five times, and 100 μL of 1-Step Ultra TMB (Fisher Scientific) was added and incubated for ~10 min at RT before addition of 100 μL Stop solution (Takara Bio, Shiga, Japan). Absorbance at 450 nm was determined using a microplate reader. Anti-mouse PD-1 (clone J43) was obtained from Thermo Fisher Scientific. Pembrolizumab and nivolumab as positive controls and standards were obtained from the Pharmacy of the University Hospital Heidelberg.

**Functional assay for pembrolizumab and nivolumab**

To assess the functionality of MeVac-encoded pembrolizumab and nivolumab, peripheral blood mononuclear cells were stimulated with the superantigen *Staphylococcus* enterotoxin B in an assay adapted from Wang et al.62 Supernatants from mock infected cells, cells infected with MeVac IgG4-Fc, and MeVac encoding pembrolizumab or nivolumab were collected. Antibody concentrations were determined using ELISA as described above. PBMCs from healthy donors were isolated using Ficoll-Hypaque by density gradient centrifugation, and 5 × 10^5 cells per well were seeded into a 96-well plate in RPMI + 5% human serum (Sigma-Aldrich). After overnight culture, SEB (Sigma-Aldrich) diluted in D-PBS was added at final concentrations of 20, 200, and 2,000 ng/mL. Cell culture supernatants from infected cells corresponding to 10 μg/mL pembrolizumab, nivolumab, or IgG4-Fc were added to respective wells. Forty and 70 h later, cell culture supernatants were collected, and IL-2 concentrations were determined using ELISA (IL-2 Human Uncoated ELISA kit; Thermo Fisher Scientific).

**Statistical analyses and visualization**

Statistical analyses were performed using GraphPad Prism version 8 (Graph Pad Software, San Diego, CA). The graphical abstract was created using BioRender.com.

**SUPPLEMENTAL INFORMATION**

Supplemental information can be found online at https://doi.org/10.1016/j.omto.2021.11.020.

**ACKNOWLEDGMENTS**

We acknowledge S. Russell, R. Cattaneo, A. Jassowicz, C. Plass, S. Eichmüller, and W. Osen for providing cell lines. We thank J. Albert, B. Hoyler, and S. Sawall for technical assistance. This work was funded by the German National Science Foundation (Deutsche Forschungsgemeinschaft, DFG, grant EN 1119/2–2 to C.E.E.), the Else Kröner-Fresenius-Stiftung (2019_EKMS.02 to C.E.E.), and the Wilhelm Sander-Stiftung (grant 2018.058.1 to C.E.E.). R.V. was supported by a scholarship from the Heidelberg School of Oncology (HSO) and by the European Regional Development Fund (ERDF) project no. 1.1.1.2/VIAA/2/18/292. G.P.-M. received a scholarship from the Helmholtz International Graduate School for Cancer Research.

**AUTHOR CONTRIBUTIONS**

Conceptualization, C.E.E. and R.V.; Methodology, R.V.; Investigation and Analyses, R.V., G.P.-M., C.M., L.M.J., and L.K.; Writing – Original Draft: R.V. and C.E.E.; Writing – Review & Editing: G.P.-M., R.V., L.M.J., and C.E.E.; Resources, G.U., C.J.B., and D.J.

**DECLARATION OF INTERESTS**

G.U. is a co-founder, stakeholder, and chief medical officer (CMO)/chief scientific officer (CSO) of CanVirex AG, a company investigating oncolytic viruses as cancer immunotherapeutics.

**REFERENCES**

1. Fardoll, D.M. (2012). The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264.
2. Ribas, A., and Wolchok, J.D. (2018). Cancer immunotherapy using checkpoint blockade. Science 359, 1350–1355.
3. Sharpe, A.H., and Pauken, K.E. (2018). The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153–167.
4. Okazaki, T., and Honjo, T. (2007). PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19, 813–824.
5. Chamoto, K., Hatae, R., and Honjo, T. (2020). Current issues and perspectives in PD-1 blockade cancer immunotherapy. Int. J. Clin. Oncol. 25, 790–800.
6. Nowicki, T.S., Hu-Lieskovski, S., and Ribas, A. (2018). Mechanisms of resistance to PD-1 and PD-L1 blockade. Cancer J. 24, 47–53.

7. Tumeh, P.C., Harvie, C.L., Yearley, J.H., Shin, T., Taylor, E.J., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571.

8. Misich, J.M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahloda, R., Hellbecque, A., et al. (2016). Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur. J. Cancer 54, 139–148.

9. Achar, C., Surendran, A., Wedge, M.E., Ungerechts, G., Bell, J., and Ilkow, C.S. (2018). Lighting a fire in the tumor microenvironment using oncolytic immunotherapy. ElieMedicine 31, 17–24.

10. Liu, Z., Ravinrathan, R., Kalinski, P., Guo, Z.S., and Bartlett, D.L. (2017). Rational combination of oncolytic vaccinia virus and PD-L1 blockade works synergistically to enhance therapeutic efficacy. Nat. Commun. 8, 14754.

11. Goepfert, K., Dinsart, C., Rommelae, J., Foerster, F., and Moehler, M. (2019). Rational combination of parvovirus H1 with CTLA-4 and PD-1 checkpoint inhibitors dampens the tumor induced immune silencing. Front Oncol. 9, 425.

12. Engeland, C.E., Grossardt, C., Veinalde, R., Bossow, D., Lutz, D., Kaufmann, J.K., Goepfert, K., Dinsart, C., Rommelaere, J., Foerster, F., et al. (2019). Oncolytic Maraba virus armed with tumor antigen boosts vaccine priming and reveals diverse therapeutic response patterns when combined with checkpoint blockade in ovarian cancer. J. Immunother. Cancer 7, 189.

13. Rajani, K., Parthish, C., Kotte, T., Thompson, J., Zaidi, S., Ilett, L., Shim, K.G., Diaz, R.M., Pandha, H., Harrington, K., et al. (2016). Combination therapy with reovirus and anti-PD-1 blockade controls tumor growth through innate and adaptive immune responses. Mol. Ther. 24, 166–174.

14. Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R.H.I., Michielin, O., Olzanski, A.J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2018). Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 174, 1031–1052.

15. Sun, L., Funchain, P., Song, J.M., Rayman, P., Tannenbaum, C., Ko, J., McNamara, M., Marcela Diaz-Montero, C., and Gastman, B. (2018). Talimogene laherparepvec therapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 174, 1031–1052.

16. Sivanandam, V., LaRocca, C.J., Chen, N.G., Fong, Y., and Warner, S.G. (2019). Oncolytic Measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer. EBioMedicine 22, 533–541.

17. Packiriswamy, N., Upreti, D., Zhou, Y., Khan, R., Miller, A., Diaz, R.M., Rooney, C.M., Dispenzieri, A., Peng, K.W., and Russell, S.J. (2020). Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma. Leukemia 34, 3310–3322.

18. Veinadle, R., Grossardt, C., Hartmann, L., Bourgeois-Daigneault, M.C., Bell, J.C., Jäger, D., von Kalle, C., Ungerechts, G., and Engeland, C.E. (2017). Oncolytic measles virus encoding interleukin-12 mediates potent antitumor effects through T cell activation. Oncoimmunology 6, e1285992.

19. Hardcastle, J., Mills, L., Malo, C.S., Jin, F., Kurokawa, C., Geekyianage, H., Schroeder, M., Sarkaria, J., Johnson, A.J., and Galanis, E. (2017). Immunovirotherapy with measles virus strains in combination with anti-PD-1 antibody blockade enhances anti-tumor activity in glioblastoma treatment. Neuro Oncol. 19, 493–502.

20. Speranza, M.C., Passaro, A., Ricklefs, F., Kasai, K., Klein, S.R., Nakashima, H., Kaufmann, J.K., Ahmed, A.K., Nowicki, M.O., Obi, P., et al. (2018). Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol. 20, 225–235.

21. Dekkers, G., Bentlage, A.E.H., Segmam, T.C., Howie, H.L., Lissenberg-Thunnissen, S., Zimring, J., Rispens, T., and Vidarsson, G. (2017). Affinity of human IgG subclasses to mouse Fc gamma receptors. M Abs 9, 767–773.

22. Ungerechts, G., Springfeld, C., Frenzeke, M.E., Lampe, J., Parker, W.B., Sorscher, E.J., and Cattaneo, R. (2007). An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol. Ther. 15, 1991–1997.

23. Hammond, A.L., Plemer, R.K., Zhang, J., Schneider, U., Russell, S.J., and Cattaneo, R. (2001). Single-chain antibody displayed on a recombinant measles virus confers entry through the tumor-associated carcinoembryonic antigen. J. Virol. 75, 2087–2096.

24. Reul, J., Frisch, J., Engel, C.E., Thalheimer, F.B., Hartmann, J., Ungerechts, G., and Buchholz, C.J. (2019). Tumor-specific delivery of immune checkpoint inhibitors by engineered AAV vectors. Front Oncol. 9, 52.

25. Umadha, S., Neftelno, S.T., Hodge, J.P., Olivera, C., Campbell, J.R., and Yu, J.X. (2021). Combinations take centre stage in PD1/PDL1 inhibitor clinical trials. Nat. Rev. Drug Discov. 20, 168–169.

26. Lichty, B.D., Breitbach, C.J., Stoeld, D.F., and Bell, J.C. (2014). Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559–567.

27. Tomwaas-Boateng, K., Attigrew, J., Khwaja, M., Kitchener, A., Koopman, G., and Cattaneo, R. (2007). An immunocompetent murine model for oncolysis with an armed and targeted measles virus. Mol. Ther. 15, 1991–1997.

28. Mihalov, E., Rabinovich, A., Schumacher, R., and Mihalov, E. (2019). Antibodies that deplete PD-1+ T cells present an inconvenienteveve in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481.

29. Chen, X., Song, X., Li, K., and Zhang, T. (2019). Fc “Blocking” antibodies that deplete PD-1(+) T cells present an inconvenienceve in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481.

30. Chen, X., Song, X., Li, K., and Zhang, T. (2019). Fc “Blocking” antibodies that deplete PD-1(+) T cells present an inconvenienceve in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481.

31. Chen, X., Song, X., Li, K., and Zhang, T. (2019). Fc “Blocking” antibodies that deplete PD-1(+) T cells present an inconvenienceve in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481.

32. Chen, X., Song, X., Li, K., and Zhang, T. (2019). Fc “Blocking” antibodies that deplete PD-1(+) T cells present an inconvenienceve in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481.

33. Chen, X., Song, X., Li, K., and Zhang, T. (2019). Fc “Blocking” antibodies that deplete PD-1(+) T cells present an inconvenienceve in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481.

34. Chen, X., Song, X., Li, K., and Zhang, T. (2019). Fc “Blocking” antibodies that deplete PD-1(+) T cells present an inconvenienceve in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481.

35. Chen, X., Song, X., Li, K., and Zhang, T. (2019). Fc “Blocking” antibodies that deplete PD-1(+) T cells present an inconvenienceve in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481.

36. Chen, X., Song, X., Li, K., and Zhang, T. (2019). Fc “Blocking” antibodies that deplete PD-1(+) T cells present an inconvenienceve in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481.

37. Chen, X., Song, X., Li, K., and Zhang, T. (2019). Fc “Blocking” antibodies that deplete PD-1(+) T cells present an inconvenienceve in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481.

38. Chen, X., Song, X., Li, K., and Zhang, T. (2019). Fc “Blocking” antibodies that deplete PD-1(+) T cells present an inconvenienceve in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481.

39. Chen, X., Song, X., Li, K., and Zhang, T. (2019). Fc “Blocking” antibodies that deplete PD-1(+) T cells present an inconvenienceve in preclinical immunotherapy experiments. Eur. J. Immunol. 51, 1473–1481.
PD-1 checkpoint restraints T cell immunity in tumor-draining lymph nodes. Cancer Cell 38, 685–700.e688.

42. Welstead, G.G., Iorio, C., Draker, R., Bayani, J., Squire, J., Vongprun sawadw, S., Cattaneo, R., and Richardson, C.D. (2005). Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. Proc. Natl. Acad. Sci. U S A. 102, 16415–16420.

43. Backhaus, P.S., Veinalde, R., Hartmann, L., Dunder, J.E., Jeworowski, L.M., Albert, J., Hoyler, B., Poth, T., Jäger, D., Ungerechts, G., et al. (2019). Immunological effects and viral gene expression determine the efficacy of oncolytic measles vaccines encoding IL-12 or IL-15 agonists. Viruses 11, 914.

44. Veinalde, R., Pidelaserra-Marti, G., Heidbuechel, J.P., Kang, N., Abate-Daga, D., Ball, C.R., Ungerechts, G., and Engeland, C.E. (2019). Translational research on synergy of PD-1 checkpoint blockade and oncolytic measles virotherapy. Mol. Ther. 27, 124.

45. Borcoman, E., Kanjanapan, Y., Champiat, S., Kato, S., Servois, V., Kurzrock, R., Goel, S., Bedard, P., and Le Tourneau, C. (2019). Novel patterns of response under immunotherapy. Ann. Oncol. 30, 385–396.

46. Hsu, J., Hodgins, J.J., Marathe, M., Nicolai, C.J., Bourgeois-Daigneault, M.C., Trevino, T.N., Azimi, C.S., Scheer, A.K., Randolph, H.E., Thompson, T.W., et al. (2018). Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J. Clin. Invest 128, 4654–4668.

47. Pitt, J.M., Vétizou, M., Daillère, R., Roberti, M.P., Yamazaki, T., Routy, B., Lepage, P., Cattaneo, R., and Richardson, C.D. (2005). Measles virus replication in lymphatic cells and organs of CD150 (SLAM) transgenic mice. Proc. Natl. Acad. Sci. U S A. 102, 16415–16420.

48. Speck, T., Heidbuechel, J.P., Veinalde, R., Jaeger, D., von Kalle, C., Ball, C.R., Ungerechts, G., and Engeland, C.E. (2018). Targeted BITE expression by an oncolytic vector augments therapeutic efficacy against solid tumors. Clin. Cancer Res. 24, 2128–2137.

49. Keenan, T.E., Burke, K.P., and Van Allen, E.M. (2019). Genomic correlates of response to immune checkpoint blockade. Nat. Med. 25, 389–402.

50. Kalbasi, A., and Ribas, A. (2020). Tumor-intrinsic resistance to immune checkpoint blockade. Nat. Rev. Immunol. 20, 25–39.

51. Nakamura, T., Peng, K.W., Harvey, M., Greiner, S., Lorimer, I.A., James, C.D., and Russell, S.J. (2005). Rescue and propagation of fully retargeted oncolytic measles viruses. Nat. Biotechnol. 23, 209–214.

52. Robbins, P.F., Kantor, J.A., Salgaller, M., Hand, P.H., Fernsten, P.D., and Schlom, J. (1991). Transduction and expression of the human carcinoembryonic antigen gene in a murine colon carcinoma cell line. Cancer Res. 51, 3657–3662.

53. Lei, J., Osen, W., Gardyan, A., Hotz-Wagenblatt, A., Wei, G., Gissmann, L., Eichmüller, S., and Löchelt, M. (2015). Replication-competent foamy virus vaccine vectors as novel epitope scaffolds for immunotherapy. PLoS One 10, e0138458.

54. Samorski, R., Gissmann, L., and Osen, W. (2006). Codon optimized expression of HPV 16 E6 renders target cells susceptible to E6-specific CTL recognition. Immunol. Lett. 107, 41–49.

55. Calazan, P., and Roux, L. (1993). The role of sialic acid in efficient replication of Sendai virus defective interfering RNA. J. Virol. 67, 4822–4830.

56. Radecke, F., Spielhofer, P., Schneider, H., Kaelin, K., Huber, M., Dötsch, C., Christiansen, G., and Billeter, M.A. (1995). Rescue of measles viruses from cloned DNA. Embo J. 14, 5773–5784.

57. Martin, A., Staehehl, P., and Schneider, U. (2006). RNA polymerase II-controlled expression of antigenomic RNA enhances the rescue efficacy of two different members of the Mononegavirales independently of the site of viral genome replication. J. Virol. 80, 5708–5715.

58. Heidbuechel, J.P.W., and Engeland, C.E. (2019). Paramyxoviruses for tumor-targeted Immunomodulation: design and evaluation ex vivo. J. Vis. Exp. 143, e58651.

59. Roeden, C.T., Schindelin, J., Hiner, M.C., DeZonia, B.E., Walter, A.E., Arena, E.T., and Eliceiri, K.W. (2017). ImageJ2: ImageJ for the next generation of scientific image data. BMC Bioinformatics 18, 529.

60. Amsen, D., de Visser, K.E., and Town, T. (2009). Approaches to determine expression of sendai virus defective interfering RNA. In Oncolytic Viruses, 2019/09/06 Edn, Ed. C.E. Engeland, ed. (Humana), pp. 213–227.

61. Veinalde, R. (2020). Evaluation of oncolytic virus-induced therapeutic tumor vaccination effects in murine tumor models. In Oncolytic Viruses, 2019/09/06 Edn, 2058, C.E. Engeland, ed. (Humana), pp. 213–227.

62. Wang, C., Thudium, K.B., Han, M., Wang, X.T., Huang, H., Feingersh, D., Garcia, C., Wu, Y., Kuhne, M., Srivanasan, M., et al. (2014). In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol. Res. 2, 846–856.